Object Details
- Genentech, Inc.
- Description (Brief)
- (From box) For intravitreal injection only.
- (From insert) LUCENTIS is indicated for the treatment of patients with:
- --NEovascular (Wet) Age-Related Macular Degeneration
- --Macular Edema Followign Retinal Vein Occlusion
- --Diabetic Macular Edema
- Location
- Currently not on view
- Credit Line
- Gift of Genentech, Inc.
- ca 2013
- product expiration date
- 2015-07
- ID Number
- 2013.0069.07
- catalog number
- 2013.0069.07
- accession number
- 2013.0069
- Object Name
- pharmaceutical
- biological
- Physical Description
- glass (overall material)
- plastic (overall material)
- metal (overall material)
- paper (overall material)
- cardboard (overall material)
- Ranibizumab, 0.5 mg (overall ingredient)
- Measurements
- overall: 3/4 in x 2 5/8 in x 3 1/2 in; 1.905 cm x 6.6675 cm x 8.89 cm
- bottle of lucentis: 1 1/2 in x 5/8 in; 3.81 cm x 1.5875 cm
- filter needle: 3/4 in x 3 5/8 in x 1/4 in; 1.905 cm x 9.2075 cm x .635 cm
- precisionglide needle: 3/4 in x 3 3/16 in x 1/4 in; 1.905 cm x 8.09625 cm x .635 cm
- overall: 3 1/2 in x 2 1/2 in x 3/4 in; 8.89 cm x 6.35 cm x 1.905 cm
- place made
- United States: California, South San Francisco
- See more items in
- Medicine and Science: Medicine
- Health & Medicine
- The Antibody Initiative
- Antibody Initiative: Monoclonal Antibodies
- National Museum of American History
- Record ID
- nmah_1445181
- GUID (Link to Original Record)
- https://n2t.net/ark:/65665/ng49ca746b3-0e3d-704b-e053-15f76fa0b4fa
.jpg)
